Patent Pool (Medicines Patent Pool) announced the extension of the license for atazanavir (Atazanavir) for Ukraine and 11 other countries. This protease inhibitor is recommended by the WHO for the treatment of HIV as a second-line drug.
It is reported by the All-Ukrainian Network of People Living with HIV.
"Within the framework of this license, 6 plants can supply the generic version of atazanavir, three of which have been re-qualified by the WHO or received FDA authorization. You can predict the high competition for this drug, which will lead to affordable prices," said Director of Policy and Advocacy of the All-Ukrainian Network of PLHIV Sergiy Dmytriev .
It should be noted that the deal was reached with the pharmaceutical company Bristol-Myers Squibb on the distribution and production of atazanavir (ATV).
